Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 3/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.31 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19919643 | 0.94 | METAP2 (0.34) | XDHMETAP2KIF11ARCYP11B1 | |
| SCHEMBL23487296 | 0.91 | ABCG2 (0.34) | XDHKIF11ARCYP11B1CYP11B2 | |
| SCHEMBL19917957 | 0.91 | AR (0.36) | XDHKIF11ARCYP11B1CYP11B2 | |
| SCHEMBL19909007 | 0.91 | METAP2 (0.34) | XDHMETAP2ARCYP11B1CYP11B2 | |
| SCHEMBL19919747 | 0.91 | METAP2 (0.34) | XDHMETAP2ARCYP11B1CYP11B2 | |
| SCHEMBL19918025 | 0.90 | AR (0.41) | XDHKIF11ARCYP11B1CYP11B2 | |
| SCHEMBL19919645 | 0.90 | METAP2 (0.36) | XDHMETAP2ARCYP11B1CYP11B2 | |
| SCHEMBL19909076 | 0.90 | KIF11 (0.43) | XDHKIF11ARABCG2KDM4E | |
| SCHEMBL19913254 | 0.90 | AR (0.34) | XDHMETAP2KIF11ARCYP11B1 | |
| SCHEMBL22822682 | 0.89 | RXRA (0.39) | XDHMETAP2KIF11ARCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11588114-B2 | Organic molecules for use in optoelectronic devices | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-02-21 | — | — | US | disclosed |
| US-20200212316-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200212316-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | OR10J3, OPRM1, OR51E2 | XDH 483/4885METAP2 2365/4885KIF11 3067/4885 |
| US-11588114-B2 | Organic molecules for use in optoelectronic devices | OR10J3, OPRM1, OR51E2 | XDH 483/4885METAP2 2365/4885KIF11 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.